Meeting
2023 ASCO Annual Meeting
NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).
Authors
Edwin P Hui
Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong
Edwin P Hui , Brigette Ma , Darren Wan-Teck Lim , WK Jacky Lam , Yoke Lim Soong , Leung Li , Kenneth C.W. Wong , Daisy Lam , Florence Mok , Macy Tong , Darren MC Poon , Chi Hang Wong , Frankie Mo , Ann Dorothy King , Kwok-Wai Lo , Jason Y.K. Chan , KC Allen Chan , Anthony T. C. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03734809
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6010)
DOI
10.1200/JCO.2023.41.16_suppl.6010
Abstract #
6010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
First Author: Manabu Muto
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
First Author: Shilpa Gupta
Poster
2023 ASCO Genitourinary Cancers Symposium
HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.
First Author: Jason Brown
Poster
2022 ASCO Annual Meeting
Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.
First Author: Manuel Rodrigues